Status:
RECRUITING
Study of ZG005 in Patients With Advanced Solid Tumors
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Advanced Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant t...
Eligibility Criteria
Inclusion
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-75 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;
- Life expectancy ≥ 12 weeks;
- Histologically or cytologically confirmed diagnosis of advanced solid tumors.
Exclusion
- Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
- Any other malignancy within 5 years.
Key Trial Info
Start Date :
June 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06927687
Start Date
June 13 2025
End Date
June 1 2027
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China